Tod Woolf
Executive Director, Technology Ventures Office @Beth Israel Deaconess Medical Center
Signup · Get unlimited contacts
WORK HISTORY
Executive Director, Technology Ventures Office @Beth Israel Deaconess Medical Center
Boston, MA, US
Lead BIDMC’s Technology Ventures Office that manages intellectual property, negotiates pre-clinical industry sponsored research agreements and negotiates licensing agreements. Support our Harvard Medical School faculty members in the development of novel technologies and spinout companies. Expanded the Technology Ventures Office (TVO) team and launched a Venture Mentor program. Work with Faculty and staff to substantially increase revenues from licensing, translational research grants and industry sponsored research, while launching and renewing alliances with major biopharma and VCs. Serve on committees to establish long term plans for research and education at BIDMC, leading to formation of four translational research hubs. Collaborated with faculty and staff to create a new BIDMC comprehensive business development pitch deck for licensing and alliances. Collaborated with the TVO team to develop a series of educational seminars in technology development and technology transfer. Worked with staff to streamline the technology transfer processes, deploy an integrated IP management and IP promotion system and create an automated tech transfer-training module with an integrated invention assignment function.
EDUCATION
Harvard University
MS, PhD, Molecular and Cellular Biology
University of Michigan
Honor BS, Molecular and Cellular Biology
ABOUT TOD WOOLF
Innovative developer of biomedical technologies. Experienced in Academic Technology Transfer, BD, IP management & translation of scientific platforms into products. Communication skills demonstrated by publications, presentations including keynote addresses and team building. Generated >$250M in grant, alliance, licenses & equity revenues. Co-developed Therapeutic Editing™(1995), MOD mRNA Therapeutics™ & Vax platform (1997), STEALTH RNAi™(2003), Self-Delivering RNAi™(2009). Co-founded Sequitur, acquired by Invitrogen and RXi (public, 2008), ETAGEN & participated in formation of more than twenty other startups. Served as CBO at X-Body (acquired by Juno). KEY PATENTS, PUBS & PRODUCTS 1) THERAPEUTIC RNA EDITING™: Pursued by ETAGEN, ProQR, Beam, Locana & Korro Woolf, et al “Towards the therapeutic editing of mutated RNA sequences” PNAS, 1995 2) mRNA THERAPEUTICS™ and Vaccines: Early patent application on MOD mRNA for protein replacement & vaccines. Pursued by Arbutus, Moderna, BioNTech & Translate Bio • Woolf, et al “Sense mRNA Therapeutics” US Pat App 60/05•••••••73) GENOME EDITING BY BASE MOD: • Woolf “Therapeutic repair of mutated nucleic acid sequences” Nature Biotech 1998 • Woolf, et al “To Cleave or not to Cleave” Nature Rev DD 2017 4) GENOME EDITING WITHOUT PROGRAMMABLE NUCLEASES: First to describe modified single-stranded DNA as guide/donor for genome editing. Pursued by ETAGEN & TruCode • “Therapeutic repair of mutated nucleic acid sequences” Woolf, Nature Biotech 1998 • Woolf et al “Compositions and methods for editing nucleic acids” US17/31••••••45) STEALTH™ RNAi (DICER SUBSTRATES): First to commercialize STEALTH RNAi pursued by Sequitur (now Thermo Fisher) and Dicerna • Woolf et al “Double-stranded oligos” US Pat. 10,106,793, 2002 • publications used STEALTH RNAi 6) SELF-DELIVERING RNAi™ 1st oligo delivery conjugate to enter clinical trials (2008). Currently pursued by RXi, UMMC & Advirna. • Woolf, et al “Reduced size self-delivering RNAi compounds” US Patent 10,041,07•••08 • Lapierre et al “Potent and systematic RNAi mediated silencing with single oligo compounds” RNA 2011 7) NEXTGEN GAPMER ANTISENSE Sequitur, Atugen & Oligo Ther,$30M sales. • Woolf et al “3 Component Chimeric Antisense Oligos” US Patent 58•••02,1996 • Used to discover the Alzheimer’s beta-secretase Nature and Science 8) OFF-TARGET EFFECTS. 1st to show off-target antisense by seed sequences. • Woolf, Melton, Jennings “Specificity of antisense oligos in vivo” PNAS 1992
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.